skip to main content

NewGen

Sagard NewGen

Sagard NewGen supports entrepreneurs in the technology and healthcare industries to accelerate their growth projects in Europe and beyond

300M+€

Pan-European fund

10-50M€

Equity ticket per transaction (at closing, excluding co-invests)

25+

Dedicated professionals including Value Creation team

25%+

Portfolio average annual revenue growth

Our strategy

Sagard NewGen makes majority or minority investments between 10M€ and 50M€ (excluding co-investors), with or without leverage, to finance expansion strategies of tech and healthcare, Europe-based companies with revenues up to 150M€, that are already profitable.

Learn more

Value creation and partnerships

Our Value Creation team and global network of seasoned advisors across industries provide portfolio companies with hands-on, expert advice in go-to-market, tech & cyber, business acceleration and M&A to help management teams meet their strategic and operational challenges. Our Partnerships team also facilitates long-term commercial collaboration opportunities.

Located in Europe and North America, the support teams have the skills and experience to provide expertise in many parts of the world.

Learn more

Our responsibility commitment

In the firm belief that responsible investment creates value for all, Sagard NewGen strives to play an active role in promoting a responsible investment culture. Our commitment to responsible investment is embedded in our relationships with our employees, as well as in our role as an investor and active owner of the companies that we support.

Learn more

Our portfolio companies

The companies we invest in all share the same innovation focus and a strong drive to offer their clients the best products and service levels.

See all NewGen companies

Our latest news

View all news

Sagard NewGen strengthens its team

Jun 20, 2023

Portfolio Updates

La folle histoire de Asobo Studio sur Konbini (Available in French only)

Dec 10, 2022

Portfolio Updates

Sagard NewGen est heureux de réinvestir dans les Laboratoires Delbert, aux côtés de Vivalto Partners et des actionnaires historiques, afin de soutenir le développement de la société dans le domaine des médicaments essentiels et orphelins (FR only)

Apr 24, 2023

View all news

Disclaimer

Sustainability-related information is published on a dedicated “Intralinks” website only accessible to investors in Sagard SAS funds, in a section dedicated to information on environmental, social and quality of governance matters, in the same way as information provided in Article 10 of Regulation (EU) 2019/2088 of the European Parliament and of the Council of 27 November 2019.

Connect with us

Get in touch
Back To Top